Just a Coincidence? But another researcher says the finding is probably just coincidence. "It just shows that common diseases in teens occur commonly," says Zoe D. Draelos, MD, consulting professor of dermatology at Duke University School of Medicine in Durham, N.C. "Acne and ADHD are both common in teens." That said, "acne can be disabling psychologically to teens," Draelos tells WebMD. "It sometimes gets taken too lightly," she says. These findings were presented at a medical conference. They should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.
Thursday, March 22, 2012
治療痘痘能改善過動兒注意力嗎?
Just a Coincidence? But another researcher says the finding is probably just coincidence. "It just shows that common diseases in teens occur commonly," says Zoe D. Draelos, MD, consulting professor of dermatology at Duke University School of Medicine in Durham, N.C. "Acne and ADHD are both common in teens." That said, "acne can be disabling psychologically to teens," Draelos tells WebMD. "It sometimes gets taken too lightly," she says. These findings were presented at a medical conference. They should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.
陳冲指示..張善政政務協助台灣生技產業
血寶 (完整療程29萬!!) 用於癌症疲憊症
懷特今年可望轉盈【2012/03/23經濟日報】懷特生技(4108)昨(22)日表示,該公司新藥「血寶」將在第二季前出貨,目前已在各大醫院完成進藥手續,預估下半年起可望挹注營收,今年可望拚轉盈。懷特為美吾華關係企業,懷特昨日股價受此消息激勵,以40.3元漲停收,上漲2.6元;法人推估,該公司去年稅後虧損約2億元。據了解,懷特血寶新藥,自1998年從美商泛華技轉後,從研發、試驗到新藥查驗登記階段共歷經13年,為國內第一個植物新藥;並於2008年以「癌因性疲憊症」申請新藥許可。懷特表示,當初申請藥證時,由於衛生署食品藥物管理局(TFDA)甫成立,而沒有審查任何新藥經驗,因此好事多磨,在2010年6月才取得衛生署核可的新藥許可證,是台灣第一個由國人自行完成的植物新藥。懷特表示,血寶是針對癌症病患因治療癌症療程中,導致的中、重度疲憊症,主要對象鎖定癌末病患,病患每次療程使用24支針劑,每支售價約1.2萬元。此外,目前可供量產的新廠已經整建完畢,年產能約20萬支,最大產能可達40萬支。分析師說,該藥物初期市占率估計約3%到5%,若以每年5萬名癌末病患估算,每位病患使用一組藥品,樂觀估計將貢獻懷特約3到5億元營收;再以毛利率六到八成計,則獲利可望上看2到3億元。懷特表示,血寶目前在國內各大醫學中心,已經完成進藥審查程序,下個月即可出貨;此外,血寶目前也在美國食品暨藥物管理局(FDA)以罕見疾病的模式,進行臨床二期試驗資料整理,若順利則今年可望取得孤兒藥認證。此外,懷特指出,該公司旗下新藥糖寶、骨寶,目前都在美國FDA臨床二期階段;其中,骨寶已經向美國FDA繳交去年年度報告,並開始進行臨床結案分析;而糖寶正在臨床二期試驗,最快今年可望傳出佳音。
東洋(東曜蘇州廠) Q3 啟動中國癌症藥製造!!
濟生取代中化 供應佳醫3年洗腎液
去年股息/五鼎4.99元濟生0.35元【2012/03/22經濟日報】血糖測試廠五鼎生技(1733)、濟生藥廠昨(21)日公布,董事會通過100年財報;五鼎獲利成長16%,每股稅後純益為5.51元,每股配發現金4.99元。五鼎今年前二月營收3.33億元,年增47.36%,法人估,五鼎首季營運暢旺,可望突破5億元,年增率四成。濟生藥廠也公布去年獲利及股利分派政策,去年每股純益0.49元,每股配發現金股利0.35元。濟生去年獲得佳醫集團血液透析粉代工三年長約,目前將進一步擴充產能。法人表示,佳醫每年對外採購洗腎液(粉)約340萬桶(包),今年起將挹注濟生上億元營收。濟生去年稅後純益約2,470萬元,每股純益0.49元。去年佳醫原向中化購買洗腎液,因中化目前在產線有其他規劃,不再提供佳醫,因此佳醫轉向濟生代工,雙方簽訂三年以上長約。業界指出,目前台灣約有6萬名需要洗腎的病人,每位病人每個月平均接受12至13次洗腎治療,總計洗腎市場規模約300億元。單就洗腎液而言,一包或一桶洗腎液售價約230元,每位病人每次療程約需三桶,佳醫每年採購量約340萬桶,市占率約35%。法人預估,濟生承接佳醫這項業務後,今年起獲利可望成長,獲利上看億元。美時藥廠昨天也公布將現金增資及發行有擔保可轉換公司債。美時表示,現增金額約2億元,公司債約4億元,總共6億元,主要用於新品項研發、購買機器設備及償還借款。美時說,去年申請經濟部約2.7億元的科專補助計畫,在計畫未核准前,公司先墊支1億多元,導致去年稅後虧損約3,000萬元。